StocksMedium•3 November 2026•
1 min read
Sanofi Terminates SAR448272 Drug Program and Phase 1 Trial with Nurix Therapeutics
Key Facts
1Sanofi notified Nurix of its decision to discontinue the Phase 1 clinical trial of SAR448272 and terminate the program.
Sanofi notified Nurix Therapeutics of its decision to discontinue the Phase 1 clinical trial of SAR448272 and terminate the program. GlobeNewswire reported that the discontinuation affects the oral STAT6 degrader, which was being developed under a collaboration agreement between the two pharmaceutical companies.
NRIX closed at $25.7 on November 2, 2026, while SNY closed at $45.55 on the same date. The termination follows Sanofi's 2025 exercise of its license extension option for two programs targeting transcription factors for autoimmune and inflammatory diseases, which included the now-discontinued STAT6 program.